2 recruiting, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow BTKi: new trials by email Literature Review of BTKi trials Research Report on BTKi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-01 | 2026-05-20 |
| Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL ZO - Initial MZL, Untreated MZL | Phase 2 | Recruiting | Li Zhiming | 33 | 2024-11-13 | 2025-05-22 |
Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Rituximab (1) · acalabrutinib (1) · glofitamab (1) · zanubrutinib (1)
Li Zhiming (1) · M.D. Anderson Cancer Center (1) · University of California, Irvine (1)
United States (2) · China (1)
Catherine C Coombs, MD (1) · Preetesh Jain, MD (1)